Dyne Therapeutics (DYN) announced the appointment of Vikram Karnani to its Board of Directors. Karnani brings extensive commercial and executive leadership experience in rare disease and biopharmaceuticals, serving as the current CEO of Collegium Pharmaceutical (COLL)
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne Therapeutics price target lowered to $36 from $38 at Evercore ISI
- Dyne Therapeutics price target raised to $39 from $36 at Stifel
- Dyne Therapeutics Announces Upsized Public Offering
- Amazon initiated, GE Vernova upgraded: Wall Street’s top analyst calls
- Oppenheimer upgrades Dyne Therapeutics to Outperform, raises target to $40